Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol with Liposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer
NCT03883919Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of paricalcitol in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Started Jul 2019; status: completed.
02
Drugs
paricalcitol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03883919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883919.